Aims: To re-analyse, using a series of alternative hypoglycaemia definitions, the data from 2 trials, DUAL I and V, in which the once-daily, fixed ratio combination of insulin degludec/liraglutide (IDegLira) was compared with basal insulin therapy.
| INTRODUCTION
Insulin degludec/liraglutide (IDegLira) is a once-daily combination of insulin degludec (IDeg), a basal insulin with a long duration of action, 1 and the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide. In clinical trials, IDegLira has been associated with lower rates of hypoglycaemia vs the basal insulin comparators of IDeg (in the DUAL I clinical trial, NCT01336023) 2 and insulin glargine (IGlar) U100
(in the DUAL V clinical trial, NCT01952145), 3 despite achieving significantly better glycaemic control.
The aim of the present study was to re-analyse, using a series of alternative hypoglycaemia definitions, the data from 2 trials, DUAL I and V, in which IDegLira was compared with basal insulin therapy. In the DUAL I and DUAL V trials, the original definition of confirmed hypoglycaemia used was plasma glucose <3.1 mmol/L (<56 mg/dL) or patient unable to self-treat, and an episode was classified as nocturnal hypoglycaemia if occurring between 12:01 AM and 5:59 AM (both inclusive); however, several other definitions of hypoglycaemia are described in the literature, and have been used across different diabetes clinical trials. 4 The rates of hypoglycaemia reported in a clinical trial will inevitably be affected by the definitions used. 5 Recently, the International Hypoglycaemia Study Group released a joint American Diabetes Association (ADA)/European Association for the Study of Diabetes statement stating that a single glucose level should be agreed to, which would allow efficacy of intervention comparisons to be made with greater statistical power. 6 It is also possible that any differences in outcomes associated with differing dosing times, for example, the rate of nocturnal hypoglycaemia, could be masked by the overall hypoglycaemia advantages reported for IDegLira in these studies. The hypoglycaemia results, therefore, were also analysed by dosing time, and by varying the definition of the nocturnal period to better characterize the clinical profile of IDegLira with regard to its relative risks for hypoglycaemia. In addition, previous analyses have shown that IDegLira is efficacious regardless of baseline characteristics, such as BMI 7 and glycated haemoglobin (HbA1c). 8 In the present analysis, we assessed whether the relative risk of hypoglycaemia was influenced by key baseline characteristics, again using the different definitions.
| MATERIAL AND METHODS
The DUAL I clinical trial compared the efficacy and safety of IDegLira Episodes confirmed by a plasma glucose <3.1 mmol/L (<56 mg/dL) and/or unable to self-treat occurring between 12:01 and 7:59 AM (both inclusive)
| Statistical methods
The number of hypoglycaemic events according to the definition of hypoglycaemia, dosing time and baseline characteristics was analysed based on the full analysis set using a negative binomial regression model with a log link and the logarithm of the time period in which a hypoglycaemic episode was considered treatment-emergent as offset.
The 3 | RESULTS
| Hypoglycaemia rates according to different definitions
Regardless of the hypoglycaemia definition used, rates of hypoglycaemia were lower in patients treated with IDegLira than with IDeg, for both DUAL I and DUAL I ext, or with IGlar U100 in DUAL V, but higher than in patients treated with liraglutide, for both DUAL I and DUAL I ext ( Table 2) . The lower hypoglycaemia rates in comparison with basal insulin therapy with IDeg or IGlar U100 were achieved, despite significantly greater end-of-trial HbA1c reductions with IDegLira therapy. 2, 3, 7 Estimated rate ratios for hypoglycaemia by treatment were statistically significantly lower for patients treated with IDegLira compared with IDeg or IGlar U100 for all definitions of overall hypoglycaemia, including confirmed symptomatic and ADAdocumented symptomatic episodes (DUAL I ext and DUAL V shown in Figure 1 , DUAL I shown in Figure S1 ). Very few of the total hypoglycaemia events were categorized as severe (an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); in DUAL I there were 3 severe events with IDegLira, 2 with IDeg and none with liraglutide, in DUAL I ext, at the end of 52 weeks there were 3 severe events with IDegLira (those reported in the main DUAL I trial), 2 with IDeg (those reported in the main DUAL I trial) and 2 with liraglutide, 7 and in DUAL V one severe event with IGlar U100 and none with IDegLira. whether both treatments were dosed in the morning or afternoon ( Figure 3C ).
| Confirmed and ADA-documented symptomatic hypoglycaemia rates by baseline characteristics
The analyses of confirmed hypoglycaemia and ADA-documented symptomatic hypoglycaemia definitions, according to baseline characteristics of age, gender and BMI, showed generally consistent rates for both hypoglycaemia definitions for DUAL I (Table S1A ) and DUAL V (Table S1B ) between the treatment groups. Interaction analyses showed there was no statistically significant effect of age, gender or BMI on the estimated treatment rate ratio for IDegLira vs IDeg for both confirmed and ADA-documented symptomatic hypoglycaemia (all P > .10). Comparing IDegLira with liraglutide, there was no statistically significant effect of age, gender or BMI on the estimated treatment rate ratio for confirmed hypoglycaemia (P = .2565, P = .2635
and P = .2372, respectively), but while gender and BMI had no significant effect on ADA-documented symptomatic hypoglycaemia rate ratio (P = .2090 and P = .0659 , respectively), there was a significant difference seen between age <65 and >65 years (P = .025), with the rate ratio (favouring liraglutide) being much greater for patients aged >65 years using this definition.
| Proportion of patients achieving combined endpoints
The proportions of patients achieving an HbA1c concentration of <7%, or of ≤6.5%, those achieving the HbA1c targets with no ADAdocumented symptomatic hypoglycaemia, and those achieving these targets with no ADA-documented symptomatic hypoglycaemia and no weight gain are given in Table S2 . The odds of achieving an HbA1c concentration <7% or ≤6.5% without ADA-documented symptomatic hypoglycaemia and without ADA-documented symptomatic hypoglycaemia and weight gain were significantly greater with IDegLira than with IDeg and IGlar U100 (P < .0001 for all comparisons). A greater proportion of patients reached these targets with liraglutide than with IDegLira, and this difference in odds was significant for HbA1c <7%
with no ADA-documented symptomatic hypoglycaemia or weight gain (P < .0001), HbA1c of ≤6.5% with no ADA-documented symptomatic hypoglycaemia (P = .0006) and HbA1c ≤6.5% with no ADA- is associated with low variability in the glucose-lowering effect across 24 hours and from day to day. 9 Importantly, a similar finding was made in a meta-analysis of data from trials comparing IDeg with IGlar U100. 10 In that meta-analysis, the number of episodes per PYE was again similar across different definitions of nocturnal hypoglycaemia, and the advantage of IDeg was preserved. for confirmed hypoglycaemia and nocturnal confirmed hypoglycaemia. 3 The profiles of the cumulative mean number of episodes continued to diverge throughout the trial, indicating that the difference was not just an effect of the titration phase; rather, the benefit appeared to be maintained or even to increase with time over the course of the trial. A limitation of the present study is that patients were not randomized according to dosing time. A further consideration is that hypoglycaemia data from randomized controlled trials are not necessarily indicative of real-world hypoglycaemia rates, which tend to be higher. 12 This may mean that the benefits of lower hypoglycaemia rates with IDegLira treatment, vs IDeg and IGlar U100, could be even greater in a clinical setting; however, this remains to be demonstrated, because in practice patients may not be titrated to such tight targets as in the trial setting. Another limitation of the present study is that the analyses were not adjusted for multiplicity.
In conclusion, treatment with IDegLira, in comparison with IDeg and IGlar U100, results in lower rates of hypoglycaemia, regardless of dosing time and definition of hypoglycaemia used. This effect is FIGURE 3 Estimated rate ratio of hypoglycaemia (based on original definition) by dosing time for A, IDegLira vs IDeg and B, IDegLira vs liraglutide for DUAL I and DUAL I ext and C, IDegLira vs IGlar U100 for DUAL V. Data based on the full analysis set. The number of hypoglycaemic events was analysed using a negative binomial regression model with a log link and the logarithm of the time period in which a hypoglycaemic episode was considered treatment-emergent as offset. The model included treatment, country/region and relevant stratification factors (in DUAL I/ext only) of previous OAD treatment, baseline HbA1c stratum, and substudy participation as fixed effects. CI, confidence interval; OAD, oral antidiabetic drug observed despite lower HbA1c levels being achieved with IDegLira compared with IDeg and IGlar U100. Furthermore, the baseline characteristics of sex and BMI did not have a significant effect on the rate ratios across different hypoglycaemia definitions. Patients aged >65 years had a greater reduction in hypoglycaemia than patients aged <65 years; therefore, a broad variety of patients with type 2 diabetes might expect to reach their treatment targets with low hypoglycaemia rates during treatment with IDegLira.
